




Recombinant SARS-CoV-2 Spike RBD Mutant Protein (aa 319-541, S359N) [His]

Cat. No.: VReP-051SX

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

SARS-CoV-2, Recombinant Protein, Spike RBD (YP_009724390.1) (S359N) mutant, expressed from HEK293 cells, with a polyhistidine tag at the C-terminus.

SPECIFICATIONS

Source HEK293 Cells

Tag His

Target SARS-CoV-2

Type Viral Antigens

Applications Functional ELISA, etc.

Formulation PBS, pH 7.4.

Purity >95% pure by SDS-PAGE.

Product Form Lyophilized

Storage Store at -20°C to -80°C.

Introduction The 2019 novel coronavirus, or "SARS-CoV-2", was discovered because of Wuhan virus pneumonia cases in 2019, and was named by the World Health Organization on January 12, 2020. It belongs to the beta genera of the Coronaviridae family, together with SARS coronavirus in 2003 and MERS coronavirus in 2012. The alignment between SARS-CoV-2 and 2003 SARS CoV has about 70% sequence similarity and 40% sequence similarity with MERS CoV. The coronavirus genome encodes a spike protein, an envelope protein, a membr

ane protein, and a nucleoprotein. Among them, spike protein is the most important surface membrane protein of coronavirus.

Alternative Names

2019 novel coronavirus; SARS-CoV-2; Coronaviridae
